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Summary The optimal timing of surgery is fundamental in the management of valvular mitral
regurgitation. The main indications for surgery include symptom onset, impairment of left
ventricular function, and left ventricular enlargement. Whether surgery should be performed in
asymptomatic patients with preserved ventricular function is a subject of debate that highlights
both the importance of providing surgery in expert centers and the standardization of follow-
up exams enabling recognition of mitral regurgitation at an early symptomatic stage, thus
avoiding a delayed referral of these patients. Recent studies have deﬁned important factors
allowing risk stratiﬁcation: systolic pulmonary artery pressure at rest and during exercise, and
left ventricular and left atrial size. Ultimately, decision-making needs to be individualized and
should consider individual patient-related factors and local resources, including the natural
history of the disease, the risk of surgery, and the likelihood of successful mitral valve repair,
in order to deﬁne the optimal timing of surgery and to obtain an optimal outcome with medical
and surgical management.
© 2010 Published by Elsevier Ireland Ltd on behalf of Japanese College of Cardiology.
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ntroduction
itral regurgitation is the most common form of valvular
eart disease in the community [1] and is the second most
requent valve pathology requiring heart valve surgery [2].
echanism of regurgitation
he distinction between valvular mitral regurgitation and
econdary forms of mitral regurgitation, where a morpho-
ogically normal mitral valve becomes regurgitant secondary
o left ventricular pathologies is fundamental. These latter
orms of functional mitral regurgitation are caused by an
mbalance between tethering and closing forces on the valve
s well as mitral annular dilation that can be found in coro-
ary heart disease or dilated cardiomyopathies — in these
orms, the correction of mitral regurgitation may not lead
o an improved ventricular function and surgical indications
re less well deﬁned [3].
The most common etiology of valvular mitral regurgi-
ation is myxomatous degeneration resulting in a leaﬂet
rolapse or a ﬂail leaﬂet. Post-rheumatic and post-
ndocarditic forms are rarely encountered in developed
ountries.
The mechanism of regurgitation can be identiﬁed by
chocardiography. In the majority of cases, the mechanism
an be reliably determined by 2D-transthoracic echocardio-
raphy [4]. In the presence of limited transthoracic image
uality or when the exact mechanism remains unclear, trans-
sophageal echocardiography should be performed. Also
he use of 3D-imaging, both by transthoracic and by trans-
sophageal echocardiography may be helpful in this regard
nd permits an improved visualization of valve morphology
nd precise localization of the lesion [5].
Most commonly, in valvular mitral regurgitation, the
echanism involves leaﬂet prolapse or a ﬂail leaﬂet. Such
mechanism needs to be distinguished from a restrictive
itral valve leaﬂet. The orientation of the regurgitant jet
s typically oriented toward the opposite leaﬂet in the pres-
nce of a leaﬂet prolapse and toward the same leaﬂet in the
resence of leaﬂet restriction. Ultimately, in the presence
f longstanding severe disease with a volume overloaded left
entricle, concomitant annular dilatation might be present.
systematic approach should thus be followed when assess-
ng the valve.
The exact site of pathology can be described by following
segmental nomenclature that divides both the anterior and
he posterior leaﬂet into three segments (medial, central,
nd lateral) each [6]. A comprehensive approach to assess-
ng regurgitant mitral valve morphology has been proposed
y Carpentier [6]. Such a standardized approach is particu-
arly important when discussing the ﬁndings with surgeons
o achieve optimal results in reconstructive surgery.
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uantiﬁcation of regurgitant severity
uantiﬁcation of the severity of mitral regurgitation is
fundamental part of the assessment. Most importantly,
evere regurgitation needs to be delineated from less severe
orms of the disease. The echocardiographic quantiﬁcation
f mitral regurgitation severity is challenging and ideally
omprises an integrative approach of qualitative and quanti-
ative signs [7]. Several parameters that can be categorized
nto structural, Doppler echocardiographic, and quantita-
ive parameters should be assessed and considered together
or the quantiﬁcation of mitral regurgitation severity [7]. In
ddition to quantitative parameters, speciﬁc and support-
ve signs of severity have been deﬁned. Speciﬁc signs for
he presence of a severe mitral regurgitation include a vena
ontracta width ≥0.7 cm with a large central regurgitant jet
area >40% of left atrium) or with a wall-impinging jet of any
ize, a large ﬂow convergence, systolic ﬂow reversal in the
ulmonary veins, and a prominent ﬂail mitral valve leaﬂet or
uptured papillary muscle. Supportive signs include a dense,
riangular CW Doppler MR jet, an E-wave dominant mitral
nﬂow (E > 1.2m/s) as well as an enlarged left ventricle and
eft atrium (particularly with normal left ventricular func-
ion). The quantitative parameters suggesting severe mitral
egurgitation include an effective regurgitant oriﬁce area
40 cm2, a regurgitant volume ≥60ml, and a regurgitant
raction ≥50%. Since most of the measurements enumerated
bove have methodological limitations, ideally the informa-
ion of several factors should be combined.
In addition echocardiography allows assessments of pul-
onary arterial pressure, and left ventricular size and
unction, which are all important in the timing of mitral
alve surgery.
anagement options
o far no medical therapy for valvular mitral regurgitation
s available, the only treatment option being mitral valve
urgery.
ims of a management strategy
hen managing patients with mitral regurgitation, the
reatment aims mentioned below should be achieved:
. Improving the outcome of the individual patient with
regard to long-term mortality and morbidity.
. Preserving left ventricular function.
. Achieving mitral valve repair.While there is an overlap in their ﬁnalities, from a
edical-ethical point of view there is a clear hierarchical
riority that should not be neglected and that follows the
rder of their enumeration.
Risk stratiﬁcation in valvular mitral regurgitation 257
Figure 1 Kaplan—Meier late survival of operative survivors
according to preoperative echocardiographic ejection fraction
Figure 2 Kaplan—Meier overall postoperative survival com-
pared between patients in New York Heart Association (NYHA)
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Modiﬁed from Enriquez-Sarano et al. [8] (reproduced with per-
mission).
Conventional criteria indicating surgery
The current criteria for mitral valve surgery (Table 1) have
been largely deﬁned based on preoperative determinants of
long-term postoperative outcome. Long-term outcome after
mitral valve surgery is signiﬁcantly better when the left ven-
tricular ejection fraction at the moment of surgery is greater
than or equal to 60% (Fig. 1) [8]. The presence of a left
ventricular end systolic diameter was found to be inversely
correlated with postoperative ejection fraction and a cut-
off of 45mm was proposed as a surgical indication [9,10].
In the subgroups with preserved or reduced ejection frac-
tion, long-term postoperative outcome is signiﬁcantly better
when surgery is performed in asymptomatic or mildly symp-
tomatic patients [New York Heart Association (NYHA) classes
i
a
w
t
Table 1 Indications for mitral valve surgery in patients with seve
Indication
Symptomatic patients
Asymptomatic patients with:
Left ventricular enlargement (LVESD≥ 40mm)
Left ventricular enlargement (LVESD≥ 45mm)
Left ventricular dysfunction (EF < 60%)
Pulmonary hypertension (sPAP at rest >50mmHg)
Pulmonary hypertension (sPAP during exercise >60mmHg)
Atrial ﬁbrillation
New onset atrial ﬁbrillation
Asymptomatic patients with preserved LV function:
When repair is reasonable in experienced surgical centers when
successful repair without residual mitral regurgitation >90%
When there is a high likelihood of durable repair and a low risk f
Adapted from the guidelines on the management of valve disease from
College of Cardiology/American Heart Association [AHA] [17].
LVESD, left ventricular end systolic diameter; EF, ejection fraction; sPAlasses I/II and patients in classes III/IV.
odiﬁed from Tribouilloy et al. [11] (reproduced with permis-
ion).
and II], as compared to severely symptomatic (NYHA classes
II and IV) patients (Fig. 2) [11]. In addition, patients with sig-
iﬁcant symptoms (NYHA classes III and IV) were also found
o be at a high risk of sudden death of 7.8%/year when man-
ged conservatively [12]. On the other hand, asymptomatic
r mildly symptomatic patients (NYHA classes I and II) with
ood left ventricular function (ejection fraction ≥60%) have
very low risk of sudden death (0.8%/year) [12].
he controversy of timing of surgery in
symptomatic patients
hether asymptomatic patients with severe mitral regurgi-
ation should be operated on in the absence of symptoms
s a highly controversial topic [13,14]. Enriquez-Sarano et
l. have reported a poor outcome for initially asymptomatic
ith severe mitral regurgitation deﬁned quantitatively by
he effective regurgitant oriﬁce area ≥40mm2, when man-
re valvular mitral regurgitation.
Class
ESC ACC/AHA
I I
I
I
I I
IIa IIa
IIa
IIa
IIa
likelihood of IIa
or surgery IIb
the European Society of Cardiology [ESC] [16] and the American
P, systolic pulmonary arterial pressure; LV, left ventricular.
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Figure 3 Kaplan—Meier estimates of the mean (±SE) rates of
overall survival among patients with asymptomatic mitral regur-
gitation under medical management, according to the effective
r
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Figure 5 Kaplan—Meier event-free survival. Solid black line
shows survival free of any event to indicate surgery; gray line,
survival free of symptoms; dashed line, survival free of asymp-
tomatic (asympt) LV dysfunction; and dotted line, survival free
of asymptomatic development of atrial ﬁbrillation (Aﬁb) and/or
p
M
s
a
w
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wegurgitant oriﬁce (ERO).
odiﬁed from Enriquez-Sarano et al. [15] (reproduced with per-
ission).
ged conservatively (Fig. 3) [15]. In that study also patients
ith moderate mitral regurgitation had a suboptimal out-
ome and an increased mortality [15]. A major weakness of
his study however is the fact that while the patients were
rospectively included, they did not have regularly sched-
led control exams. Furthermore, patients with an ejection
raction between 50% and 60% which would be operated
ccording to recent guidelines [16,17], were included. On
he other hand, Rosenhek et al. showed that asymptomatic
atients can be followed conservatively with a good out-
ome, when they were operated after the onset of symptoms
r when recommended cutoff-values for left ventricular size
igure 4 Kaplan—Meier overall survival of patients with
symptomatic severe degenerative mitral regurgitation man-
ged according to a watchful waiting strategy. Solid black line
ndicates total patient population; dotted line, patients with
ail leaﬂet. Pts, patients.
odiﬁed from Rosenhek et al. [18] (reproduced with permis-
ion).
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hulmonary hypertension (PHT) to indicate surgery. Pts, patients.
odiﬁed from Rosenhek et al. [18] (reproduced with permis-
ion).
nd function are reached (Fig. 4) [18]. In this study, patients
ere followed at regular intervals in a dedicated valve
linic. Yet almost half the patients had required surgery
ithin a follow-up period of 8 years (Fig. 5), emphasizing
he need for serial clinical and echocardiographical exams
18]. Patients in the study by Enriquez-Sarano et al. were
lder (61± 14 years) than in the study by Rosenhek et al.
55± 15 years), and it is known that long-term outcome,
ven after successful initial mitral valve surgery is affected
y the age at operation [19].
A recent study by Kang et al. described an excellent
utcome of asymptomatic patients with severe mitral regur-
itation undergoing early elective surgery with no cardiac
ortality (a stroke that caused death in 3 patients who
ere initially operated was considered a non-cardiac event
espite a potential relationship with a prosthetic aortic
alve) [20]. In the group that was initially managed conser-
atively, a cardiac event-rate of 15% was reported, although
t included congestive heart failure death in 5 patients
ho refused urgent surgery, death from endocarditis in 2
atients, and 1 sudden death in a patient who had become
ymptomatic as well as 22 hospitalizations because of heart
ailure, even though none of these patients died. Only, 3
ases of sudden death occurred in asymptomatic patients.
hus, these results cannot be interpreted as strong evidence
gainst an initial watchful waiting approach.
actors that should be considered when referring
atients to mitral valve surgeryhen mitral valve surgery is warranted, mitral valve repair
s the method of choice and is associated with signiﬁcantly
etter outcome compared to mitral valve replacement. The
ighest success rates of mitral valve repair are achieved
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Figure 6 Mitral valve repair rates, for isolated primary mitral
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between 50 and 70mm and 12% for left size <50mm [34].regurgitation, for the years 2000—2007 according to data from
the US Society of Thoracic Surgeons database (p < 0.0001).
Modiﬁed from Gammie et al. [25] (reproduced with permission).
when the posterior leaﬂet is involved. Meanwhile, excel-
lent long-term results of mitral valve repair are available
[21]. Nevertheless the potential necessity of reoperation
after mitral valve repair which occurs at a rate of 1% per
year [22,23], and the fact that some patients may have
variable degrees of residual mitral regurgitation — free-
dom from mitral regurgitation (>2/4) was reported to be
64.9% after 10 years [24] — need to be considered. While
selected centers may offer excellent rates of valve repair,
on a larger scale, repair is still not performed in satisfac-
tory numbers although the rates of repair have increased
from 50% in 2000 to 69% in 2007 according to the data from
the US Society of Thoracic Surgeons database (Fig. 6) [25].
In addition, operative risk, which is generally 1% for mitral
valve repair [25], may be substantially higher when valve
replacement is performed, increasing from 4% in younger
patients to 17% in octogenarians with additional increase
in mortality in the presence of comorbidity [26]. A major
contributing factor to successful valve repair is the hospital
volume: unadjusted mortality rates decreased from 3.08% in
the lowest-volume category to 1.11% in the highest-volume
category and the rates of mitral valve repair increased from
47.7% in the lowest-volume quartile to 77.4% in high-volume
hospitals [27]. At the same time the possibility of regu-
lar control visits of these patients in specialized centers
offering dedicated valve clinics is desirable. An analysis
of the EuroHeart Survey has shown that 49% of 396 symp-
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Figure 7 Kaplan—Meier overall survival according to left ventricul
regurgitation (MR): (A) with conservative management (B) with med
Modiﬁed from Tribouilloy et al. [35] (reproduced with permission).259
omatic patients with mitral regurgitation were not referred
o surgery [28]. Non-operated patients were older and more
requently had impaired left ventricular function. How-
ver, even patients without concomitant comorbidities were
enied surgery. Another aspect that needs to be consid-
red is that many patients are ﬁrst diagnosed at the stage
f advanced symptoms and that in current practice many
atients are operated with advanced symptoms (39% and
2%, NYHA classes III and IV, respectively, versus 17% and
1% in NYHA classes I and II, respectively) [25].
While these disparities call for an improvement of care
n the ﬁeld of degenerative mitral regurgitation [29], local
esources need to be considered in the decision-making pro-
ess and risk stratiﬁcation is encouraged.
isk stratiﬁcation
izarro et al. have shown that low BNP levels (<105 pg/ml)
re associated with a stable disease course whereas higher
evels may predict an unfavorable outcome [30]. In addition,
ood exercise tolerance has been shown to be associated
ith excellent outcome and a low event-rate [31]. Magne
t al. found that the occurrence of exercise pulmonary
ypertension (deﬁned by a systolic pulmonary pressure
60mmHg) was an important predictor for the onset of
ymptoms with event-free survival rates of 35± 8% as com-
ared to 75± 7% for patients without exercise pulmonary
ypertension, after 2 years [32]. In this study resting pul-
onary hypertension had a predictive value in univariate
nalysis that was not independent after correction [32].
ecently, Le Tourneau et al. found that 8-year survival after
itral valve surgery was 86.6% in patients with a baseline
ystolic pulmonary artery pressure of <50mmHg as com-
ared to 58.6% for a pressure ≥50mmHg [33]. Also left
trial size is related to outcome: patients having a left atrial
ize (measured longitudinally in a 4-chamber view) of more
han 70mm had a 53% likelihood of requiring surgery within
years as compared to 18% for left atrial size comprisedecently, Tribouilloy et al. have found that a left ventricular
nd systolic diameter ≥40mm is independently associated
ith increased mortality under medical management and
fter surgery (Fig. 7) [35].
ar end systolic diameter (LVESD) in patients with organic mitral
ical and surgical treatment.
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These ﬁndings thus suggest that patients with low BNP
evels and a good exercise tolerance can be safely followed
hen they are asymptomatic and have good left ventricular
unction. Concerning the cutoff for the left ventricular end
ystolic diameter, the cutoff value of 40mm that is proposed
y the recent American College of Cardiology/American
eart Association guidelines [17] seems to be more appro-
riate than the cutoff of 45mm suggested by the European
ociety of Cardiology guidelines [16]. The recent evidence is
lso in favor of supporting surgery in asymptomatic patients
ith systolic pulmonary hypertension that was only con-
idered a class IIb indication for surgery according to the
uidelines. Finally, left atrial size may be an important pre-
ictor to deﬁne patient subgroups who may beneﬁt from
arlier surgery.
Ultimately decision-making needs to be individualized
nd should take consideration of individual patient-related
actors and of local resources including the natural history
f the disease, the risk of surgery, and the likelihood of suc-
essful mitral valve repair in order to deﬁne the optimal
iming of surgery and to obtain an optimal outcome, with
oth medical and surgical management.
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